664 results on '"Jazaeri, Amir"'
Search Results
2. METI: deep profiling of tumor ecosystems by integrating cell morphology and spatial transcriptomics
3. A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
4. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer
5. Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis
6. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab
7. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
8. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
9. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression
10. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma
11. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival
12. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs
13. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis
14. Immuno-Oncology for Gynecologic Malignancies
15. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery.
16. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer.
17. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.
18. Clinical and genomic landscape of RAS mutations in gynecologic cancers
19. Immuno-oncology for Gynecologic Malignancies
20. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer
21. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer
22. Expression of B7–H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas
23. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction
24. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
25. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract
26. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
27. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
28. Abstract A077: The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer
29. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma
30. Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer
31. Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer
32. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial
33. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls
34. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma.
35. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation
36. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma
37. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer
38. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum‐resistant ovarian cancer
39. 1045 Overcoming immunosuppressive tumors by stimulating the adaptive and innate immune systems
40. Transforming ovarian cancer care by targeting minimal residual disease
41. SO013/#983 Intraoperative identification of ovarian cancer during tumor reductive surgery using the hand-held masspec pen technology
42. EP159/#1534 Leveraging personalized circulating tumor DNA monitoring to predict treatment response and recurrence in high-risk endometrial cancer
43. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials
44. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice
45. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy
46. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature
47. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer
48. Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from a Population-Based Study
49. Potential immunotherapy targets in recurrent cervical cancer
50. Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.